Pharmaceutical launches in 2026: coordinate SPCs, patents and regulatory milestones

horak Rechtsanwälte · Patent insights and case law

English · Deutsch · Français

A pharmaceutical launch calendar should not contain a single line labelled “patent expiry”. The relevant product may be affected by a basic patent, supplementary protection certificates, other patent families and separate regulatory protections. The operational task is to connect each legal right with the product, country and activity the business actually plans.

The current framework, not an assumed reform

Under the present SPC framework, a Unitary Patent can serve as a basic patent, but the EPO describes the resulting certificates as national SPCs. The Commission’s reform materials must not be treated as proof that a unitary SPC has already been introduced. This guide reflects the position checked on 17 November 2026. [1] [2]

Regulation 469/2009 sets conditions for medicinal-product SPCs, their protected subject matter and application deadlines. Eligibility and duration are not established merely by finding a patent number and a marketing authorisation. The exact product, patent, authorisation history and relevant dates require a separate assessment. [3]

Build one calendar with separate legal layers

Create a country-specific schedule showing the right holder, basic patent, certificate number, status and recorded expiry. Keep the underlying register extracts and authorisation documents with the calculation. Add formulation, process, dosage and medical-use patents in separate rows, rather than assuming that the main compound right exhausts the landscape. Record the planned indication, manufacturing route and product version so later reviewers can see what the clearance assessment covered.

Regulatory colleagues should identify approval steps and any data or market exclusivity issue separately. Commercial staff should identify launch commitments, supply reservations and customer penalties. Counsel can then distinguish a legal deadline from a business preference. Give each uncertain item an owner and an action date: “SPC to be checked” is not a usable instruction when packaging, manufacturing and distribution decisions are already being taken.

Prepare the evidence before the launch decision

Preserve samples, batch information and the documents supporting the chosen production route. Establish who can explain differences between the planned product and the patent claims. If urgent proceedings are foreseeable, assess what can be submitted without exposing unnecessary confidential information. Any protective-letter or preliminary-injunction strategy needs the actual facts, not just a general view that the principal patent is approaching expiry.

Review the calendar again whenever the supplier, formulation or indication changes. A clearance conclusion based on one version should not silently migrate to another. For licensing discussions, prepare a schedule of the rights and territories to be covered and identify whether past acts, launch stock and future approvals require express treatment. The same schedule helps avoid misunderstandings between the regulatory and litigation teams.

Four practical examples

1. A compound patent expires before another relevant right

A generic company plans a launch using only the best-known expiry date. A portfolio review identifies a separate formulation claim. The team evaluates the actual formulation and available alternatives before committing to stock that may require a different legal analysis.

2. The authorisation holder and patent owner differ

An acquisition team discovers that authorisation documents and patent records name different group entities. It reconstructs ownership and contractual responsibilities before approving certificate work. A familiar brand name is not used as a substitute for the underlying legal documents.

3. A supplier changes the manufacturing route

Procurement replaces a supplier to reduce cost. The new route introduces steps absent from the earlier clearance file. Technical and legal teams reassess those steps and update the evidence record before assuming that the previous launch conclusion still applies.

4. A settlement covers only the first indication

The parties agree launch terms for one indication while another remains in development. They specify whether the future indication and related regulatory changes are included. This prevents a present settlement from leaving an avoidable disagreement at the next commercial milestone.

Practical guide reviewed on 17 November 2026. The examples are hypothetical and do not describe client matters.

Official sources

1. https://www.epo.org/en/service-support/faq/law-practice/unitary-patent/supplementary-protection-certificate-spc-based

2. https://single-market-economy.ec.europa.eu/industry/strategy/intellectual-property/patent-protection-eu/supplementary-protection-certificates-pharmaceutical-and-plant-protection-products_en

3. https://eur-lex.europa.eu/eli/reg/2009/469/oj/eng

Discuss your patent matter

Please identify the patent, the affected product and any known deadline. Do not send confidential technical details before conflicts have been checked. Contact our team